Mylan N.V. (NASDAQ:MYL) : The consensus price target for Mylan N.V. (NASDAQ:MYL) is $59.14 for the short term with a standard deviation of $7.47. The most optimist securities analyst among the 7 who monitor the stock believes that the stock can reach $71, however, the pessimist price target for the company is $51.
Other Equity analysts have also commented on the company shares. In the latest statement by the brokerage house, Leerink Swann maintains its outlook on Mylan N.V. (NASDAQ:MYL). The current rating of the shares is Outperform, according to the research report released by the firm. The brokerage firm lowers the price target from $53 per share to $51 per share. The rating by the firm was issued on May 4, 2016.
Mylan N.V. (NASDAQ:MYL): stock turned positive on Thursday. Though the stock opened at $45.64, the bulls momentum made the stock top out at $46.22 level for the day. The stock recorded a low of $45.46 and closed the trading day at $46.16, in the green by 2.58%. The total traded volume for the day was 2,964,764. The stock had closed at $45 in the previous days trading.
The company shares have dropped -36.04% from its 1 Year high price. On Jul 6, 2015, the shares registered one year high at $73.90 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $43.07 and the 200 Day Moving Average price is recorded at $47.28. On the companys insider trading activities, Maroon Joseph C Md, director of Mylan N.V., executed a transaction worth $75,067 on June 3, 2016. A total of 1,670 shares were purchased at an average price of $44.95. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.